Macleod 2014 Lancet: Difference between revisions
From Bioblast
m (Iglesias-Gonzalez Javier moved page Macleod 2014 to Macleod 2014 Lancet) |
No edit summary |
||
| Line 11: | Line 11: | ||
|editor=[[Iglesias-Gonzalez J]] | |editor=[[Iglesias-Gonzalez J]] | ||
}} | }} | ||
== Cited by == | |||
{{Template:Cited by Iglesias-Gonzalez 2021 MitoFit PT}} | |||
{{Labeling | {{Labeling | ||
|additional= | |additional=MitoFit 2021 PT | ||
}} | }} | ||
Latest revision as of 11:52, 26 January 2021
| Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioanidis JPA, Salman RAS, Chan AW, Glasziou P (2014) Biomedicel research: increasing value, reducing waste.. Lancet 383(9912):101-4. |
Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioanidis JPA, Salman RAS, Chan AW, Glasziou P (2014) Lancet
Abstract: Of 1575 reports about cancer prognostic markers published in 2005, 1509 (96%) detailed at least one significant prognostic variable. However, few identifi ed biomarkers have been confirmed by subsequent research and few have entered routine clinical practice. This pattern—initially promising findings not leading to improvements in health care—has been recorded across biomedical research. So why is research that might transform health care and reduce health problems not being successfully produced?
• Bioblast editor: Iglesias-Gonzalez J
Cited by
- Iglesias-Gonzalez et al (2021) Proficiency test in mt-respiration: A necessary tool for reliable and reproducible results. MitoFit Preprints 2021 (in prep).
Labels:
MitoFit 2021 PT
